Skip to main content
Top
Published in: BMC Health Services Research 1/2013

Open Access 01-12-2013 | Research article

Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews

Authors: Danielle Bishop, Joel Lexchin

Published in: BMC Health Services Research | Issue 1/2013

Login to get access

Abstract

Background

Pressures on health care budgets have led policy makers to discuss how to balance the provision of costly technologies to populations in need and making coverage decisions under uncertainty. Coverage with evidence development (CED) is being employed to meet these challenges.

Methods

Twenty-four interviews were carried out between June 2009 and December 2010 with researchers, decision makers and policy makers from Australia, Canada, United Kingdom and United States. Three phases of coding occurred, the first being manual coding where the interviews were read and notes were taken and nodes were extracted and imputed. NVIVO coding was applied to the interview transcripts, with both broad general searches for word usages and imputed nodes.

Results

Four overarching thematic areas emerged out of contextual analysis of the interviews – (1) what constitutes CED; (2) the lack of a systematic approach/governance structure; (3) the role of the pharmaceutical industry and overt political considerations in CED; and (4) alternatives and barriers to CED. We explore these themes and then use concrete examples of CED projects in each of the four countries to illustrate the political issues that our interviewees raised.

Conclusion

Until the underlying political nature of CED is recognized then fundamental questions about its usefulness and operation will remain unresolved.
Literature
1.
go back to reference Virchow R: Report on the typhus epidemic in Upper Silesia. Collected essays on public health and epidemiology. Edited by: Rather L. 1985, Canton, MA: Science History Publications Virchow R: Report on the typhus epidemic in Upper Silesia. Collected essays on public health and epidemiology. Edited by: Rather L. 1985, Canton, MA: Science History Publications
2.
go back to reference Chalkidou K, Lord J, Fischer A, Littlejohns P: Evidence-based decision making: when should we wait for more information?. Health Aff. 2008, 27: 1642-1653. 10.1377/hlthaff.27.6.1642.CrossRef Chalkidou K, Lord J, Fischer A, Littlejohns P: Evidence-based decision making: when should we wait for more information?. Health Aff. 2008, 27: 1642-1653. 10.1377/hlthaff.27.6.1642.CrossRef
3.
go back to reference Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, Soares M, Spackman E, Youn J: Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. Health Technol Assess. 2012, 16 (46): 1-342.CrossRefPubMed Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, Soares M, Spackman E, Youn J: Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. Health Technol Assess. 2012, 16 (46): 1-342.CrossRefPubMed
4.
go back to reference Menon D, McCabe CJ, Stafinski T, Edlin R: Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit. PharmacoEconomics. 2010, 28: 109-111. 10.2165/11530860-000000000-00000.CrossRefPubMed Menon D, McCabe CJ, Stafinski T, Edlin R: Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit. PharmacoEconomics. 2010, 28: 109-111. 10.2165/11530860-000000000-00000.CrossRefPubMed
5.
go back to reference Hutton J, Trueman P, Henshall C: Coverage with evidence development: an examination of conceptual and policy issues. Int J Technol Assess Health Care. 2007, 23 (4): 425-435.CrossRefPubMed Hutton J, Trueman P, Henshall C: Coverage with evidence development: an examination of conceptual and policy issues. Int J Technol Assess Health Care. 2007, 23 (4): 425-435.CrossRefPubMed
6.
go back to reference Miller FG, Pearson SD: Coverage with evidence development: ethical issues and policy implications. Medical Care. 2008, 46: 746-751. 10.1097/MLR.0b013e3181789453.CrossRefPubMed Miller FG, Pearson SD: Coverage with evidence development: ethical issues and policy implications. Medical Care. 2008, 46: 746-751. 10.1097/MLR.0b013e3181789453.CrossRefPubMed
7.
go back to reference Stafinski T, McCabe CJ, Menon D: Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. PharmacoEconomics. 2010, 28: 113-142. 10.2165/11530820-000000000-00000.CrossRefPubMed Stafinski T, McCabe CJ, Menon D: Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. PharmacoEconomics. 2010, 28: 113-142. 10.2165/11530820-000000000-00000.CrossRefPubMed
8.
go back to reference Lexchin J: Coverage with evidence development for pharmaceuticals: a policy in evolution?. Int J Health Serv. 2011, 41: 337-354. 10.2190/HS.41.2.h.CrossRefPubMed Lexchin J: Coverage with evidence development for pharmaceuticals: a policy in evolution?. Int J Health Serv. 2011, 41: 337-354. 10.2190/HS.41.2.h.CrossRefPubMed
9.
go back to reference Charmaz K: Constructing grounded theory: a practical guide through qualitative analysis. 2006, London: Sage Charmaz K: Constructing grounded theory: a practical guide through qualitative analysis. 2006, London: Sage
10.
go back to reference Birkett DJ, Mitchell AS, McManus P: A cost-effectiveness approach to drug subsidy and pricing in Australia. Health Aff. 2001, 20: 104-114. 10.1377/hlthaff.20.3.104.CrossRef Birkett DJ, Mitchell AS, McManus P: A cost-effectiveness approach to drug subsidy and pricing in Australia. Health Aff. 2001, 20: 104-114. 10.1377/hlthaff.20.3.104.CrossRef
11.
go back to reference MacLeod S, Mitton C: We know with accuracy only when we know little. PharmacoEconomics. 2010, 28 (2): 105-107. 10.2165/11531510-000000000-00000.CrossRefPubMed MacLeod S, Mitton C: We know with accuracy only when we know little. PharmacoEconomics. 2010, 28 (2): 105-107. 10.2165/11531510-000000000-00000.CrossRefPubMed
12.
go back to reference Foucault M: The birth of biopolitics: lectures at the College de France 1978–1979. 2008, New York: Palgrave Macmillan Foucault M: The birth of biopolitics: lectures at the College de France 1978–1979. 2008, New York: Palgrave Macmillan
14.
go back to reference Keogh A, Strange G, McNeil K, Williams TJ, Gabbay E, Proudman S, Weintraub RG, Wlodarczyk J, DAlton B: The bosentan patient registry: long-term survival in pulmonary arterial hypertension. Intern Med J. 2011, 41: 227-234. 10.1111/j.1445-5994.2009.02139.x.CrossRefPubMed Keogh A, Strange G, McNeil K, Williams TJ, Gabbay E, Proudman S, Weintraub RG, Wlodarczyk J, DAlton B: The bosentan patient registry: long-term survival in pulmonary arterial hypertension. Intern Med J. 2011, 41: 227-234. 10.1111/j.1445-5994.2009.02139.x.CrossRefPubMed
15.
go back to reference Friedman LS, Richter ED: Relationship between conflicts of interest and research results. J Gen Intern Med. 2004, 19: 51-56. 10.1111/j.1525-1497.2004.30617.x.CrossRefPubMedPubMedCentral Friedman LS, Richter ED: Relationship between conflicts of interest and research results. J Gen Intern Med. 2004, 19: 51-56. 10.1111/j.1525-1497.2004.30617.x.CrossRefPubMedPubMedCentral
16.
go back to reference Wang AT, McCoy CP, Mural MH, Montori VM: Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ. 2010, 340: c1344-10.1136/bmj.c1344.CrossRefPubMedPubMedCentral Wang AT, McCoy CP, Mural MH, Montori VM: Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ. 2010, 340: c1344-10.1136/bmj.c1344.CrossRefPubMedPubMedCentral
17.
go back to reference Owen AJ, Spinks J, Meehan A, Robb T, Hardy M, Kwasha D, Wlodarczyk J: A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry. J Med Econ. 2008, 11: 235-243.PubMed Owen AJ, Spinks J, Meehan A, Robb T, Hardy M, Kwasha D, Wlodarczyk J: A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry. J Med Econ. 2008, 11: 235-243.PubMed
18.
go back to reference Ryerson CJ, Nayar S, Swiston JR, Sin DD: Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res. 2010, 11: 12-10.1186/1465-9921-11-12.CrossRefPubMedPubMedCentral Ryerson CJ, Nayar S, Swiston JR, Sin DD: Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res. 2010, 11: 12-10.1186/1465-9921-11-12.CrossRefPubMedPubMedCentral
22.
go back to reference Raftery J: Costly failure of a risk sharing scheme. BMJ. 2010, 340: 1282-1284. 10.1136/bmj.c1282.CrossRef Raftery J: Costly failure of a risk sharing scheme. BMJ. 2010, 340: 1282-1284. 10.1136/bmj.c1282.CrossRef
23.
24.
go back to reference Mohr PE, Tunis SR: Access with evidence development: the US experience. PharmacoEconomics. 2010, 28: 153-162. 10.2165/11531050-000000000-00000.CrossRefPubMed Mohr PE, Tunis SR: Access with evidence development: the US experience. PharmacoEconomics. 2010, 28: 153-162. 10.2165/11531050-000000000-00000.CrossRefPubMed
Metadata
Title
Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews
Authors
Danielle Bishop
Joel Lexchin
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2013
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/1472-6963-13-88

Other articles of this Issue 1/2013

BMC Health Services Research 1/2013 Go to the issue